Novartis halts development of cholesterol drug, will post US$266M charge

BASEL, Switzerland (AP) - Swiss drug company Novartis AG said Friday it has halted development of cholesterol drug pitavastatin and will post a charge of $266 million US in the fourth quarter as a result....More